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Abstract 
Introduction: The relationship between on-treatment platelet reactivity and cerebral 
micro-embolic signals (MES) on transcranial Doppler ultrasound (TCD) is unknown 
and has not been previously simultaneously assessed in asymptomatic and 
symptomatic carotid stenosis patients. 
Methods: Consecutive eligible patients with ≥50% asymptomatic or recently 
symptomatic carotid stenosis (≤4 weeks following TIA/ischaemic stroke) were 
recruited to this pilot study. Symptomatic patients were followed up to the ‘late’ phase 
(≥3 months) following symptom onset or carotid intervention; longitudinal data from 
symptomatic patients with data available at both time-points were compared. Platelet 
function/reactivity was assessed using the PFA-100® to measure collagen-ADP (C-
ADP) and collagen-epinephrine (C-EPI) closure times in citrate-anticoagulated whole 
blood. Bilateral simultaneous 1-hour transcranial Doppler ultrasound monitoring of 
the middle cerebral arteries was performed to classify patients as MES-positive or 
MES-negative. 
Results: 31 patients with asymptomatic and 46 with early symptomatic carotid 
stenosis or occlusion were included. 35 symptomatic patients were followed up to the 
late phase (23 following carotid intervention). Prevalence of ‘high on-treatment 
platelet reactivity’ (HTPR) on the C-EPI cartridge did not differ between 
asymptomatic and symptomatic patients overall, but was lower in ‘symptomatic post-
intervention’ than asymptomatic patients on aspirin monotherapy (10% vs. 50%; 
P=0.03). The prevalence of HTPR on the C-EPI cartridge significantly decreased 
between the early versus late phase in symptomatic patients (63% vs. 34%; P=0.017), 
including those on aspirin monotherapy (P = 0.016).  
Discussion: Carotid interventional treatment, presumably in combination with 
resolution of the acute phase response, may decrease the prevalence of HTPR in 
patients with recently symptomatic carotid stenosis over time. Preliminary subgroup 
data suggest that successful interventional treatment may even reduce the prevalence 
of aspirin-HTPR in symptomatic patients to lower levels than in asymptomatic 
patients on aspirin monotherapy. Larger, longitudinal studies are warranted to reassess 
the impact of more intensive secondary preventive treatment on ex vivo platelet 
function at different levels of shear in patients with carotid stenosis. 
Introduction 
There is evidence that platelets are excessively activated or ‘hyper-reactive’ in 
patients with TIA and ischaemic stroke versus controls,[1-7] and excessively 
activated in patients with recently symptomatic versus asymptomatic carotid 
stenosis.[2-4;8,9] There is also evidence that short-term treatment with aspirin-
clopidogrel combination therapy is more effective than aspirin monotherapy at 
preventing microembolic signals (MES) on TCD,[10] and that combination therapy 
with aspirin-dipyridamole appears equally effective as aspirin-clopidogrel at reducing 
MES in recently symptomatic carotid stenosis patients.[11] 
There is an emerging literature to suggest that data from platelet function/reactivity 
monitoring may enhance our ability to predict the risk of recurrent vascular events 
and functional outcome in patients with vascular disease.[8,12] Ischaemic heart 
disease patients on antiplatelet therapy deemed to have ‘high on-treatment platelet 
reactivity’ (HTPR) or ‘non-responsiveness’ on an ex vivo test of platelet function have 
been shown to have a higher risk of clinical outcome events than those without 
HTPR.[13-15] However, the definition of HTPR on various platelet function devices 
varies between studies.[13-18] Preliminary, hypothesis-generating, subgroup data 
analysis from one study suggested that, compared with controls, the prevalence of 
HTPR reduced in patients with severe carotid stenosis who were followed up from the 
early (≤4 weeks) to late phase (≥ 3 months) after symptom onset or intervention.[7] 
To our knowledge, no adequately powered studies have compared the prevalence of 
ex vivo HTPR in whole blood between asymptomatic and early and late phase 
symptomatic carotid stenosis patients. 
 
Prior studies have illustrated the potential role of MES detection on TCD in 
identifying asymptomatic and symptomatic carotid stenosis patients who may benefit 
most from enhanced medical or surgical therapy to prevent TIA or stroke.[19-24] To 
our knowledge, simultaneous measurement of HTPR on a point-of-care (POC) device, 
the PFA-100, has not been performed in patients with asymptomatic versus 
symptomatic carotid stenosis, in conjunction with simultaneous quantification of 
cerebral MES. 
The aims of this component of the Platelets And Carotid Stenosis (PACS) study 
were to determine whether HTPR on a moderately high shear stress test of platelet 
reactivity was more common in patients with recently symptomatic than 
asymptomatic carotid stenosis, and to longitudinally assess HTPR status in 
symptomatic patients and specific subgroups. We also aimed to determine whether 
there was any relationship between HTPR status and the presence of MES detected on 
TCD (MES +ve) versus those without (MES -ve). We prospectively planned to assess 
whether there was any relationship between HTPR and the risk of recurrent vascular 
events during follow up in symptomatic patients. We hypothesised that recently 
symptomatic patients were more likely to have an increased prevalence of HTPR than 
their asymptomatic counterparts, and that the prevalence of HTPR would decrease in 
symptomatic patients during follow up after intensive medical and/or surgical 
intervention. We also hypothesised that HTPR status might be informative in certain 
patient subgroups stratified according to MES status (MES +ve vs. MES -ve). 
Methods 
Pilot ‘symptomatic case’ vs. ‘asymptomatic case/control’, and ‘nested longitudinal 
studies in symptomatic patients’ with moderate-severe carotid stenosis was 
performed.  Consecutive eligible patients > 18 years old with asymptomatic or 
symptomatic moderate or severe carotid artery stenosis or carotid occlusion, identified 
on colour Doppler ultrasound using standardised velocity criteria,[25,26] were 
recruited from the Rapid Access Stroke Prevention (RASP) Service, vascular surgery 
or general neurology clinics, and the neurology and vascular surgery wards and stroke 
service at AMNCH and St James’s Hospitals between August 2007 and February 
2010. Patients were included in the ‘asymptomatic carotid stenosis group’ if they 
were incidentally noted to have moderate (50 - 69%) or severe (≥ 70%) carotid 
stenosis on colour Doppler ultrasound imaging (CDUS), e.g. after noting an audible 
carotid bruit or during work up for coronary artery disease.[9,19] Subjects were 
considered to be asymptomatic if they never had a prior TIA or stroke in any vascular 
territory, or had not had a carotid-territory TIA or stroke within the preceding three 
years. All demographic and vascular risk factors, and information regarding 
medication intake was recorded prospectively. 
 
Patients were included in the ‘symptomatic carotid stenosis’ group if they had a 
TIA or ischaemic stroke in the vascular territory supplied by a moderate or severe 
ipsilateral carotid stenosis or carotid occlusion within the preceding 4 weeks and the 
symptoms was attributed to the stenosed carotid artery of interest (early phase). 
These patients were reassessed at least three months after symptom onset or after 
surgical or endovascular intervention (late phase). 
 
Exclusion criteria for patients included active infection, inflammation including 
vasculitis, neoplasia, platelet count < 120 or > 450 x 109/L, recurrent TIA, stroke, 
myocardial infarction, pulmonary embolism, deep vein thrombosis or major bleeding 
requiring transfusion or major surgery within the preceding 3 months; prior history of 
primary intracerebral haemorrhage; a known bleeding or clotting diathesis or platelet 
disorder; ongoing unstable coronary or peripheral arterial disease; renal impairment 
(urea > 10 mmol/l); or other nonsteroidal anti-inflammatory drug (NSAID) intake 
within 2 weeks (apart from aspirin). Symptomatic patients were also excluded if there 
was evidence of a potential cardio-embolic source detected within 3 months of 
recruitment.  
 
All patients underwent a detailed general and neurological assessment by the Clinical 
Neurology Research Registrars (JAK or WOT) or Consultant Vascular Neurologist 
(DJHM) participating in the study, to confirm that the asymptomatic patients met 
inclusion criteria, and to confirm a diagnosis of atherothrombotic TIA or ischaemic 
stroke in the symptomatic cohort. Information regarding vascular risk factors and 
medication intake, including anti-plalelet, anti-coagulant, statin and anti-hypertensive 
therapy, dose and duration of therapy were also recorded prospectively at each visit.  
CT and/or MRI brain was performed in all symptomatic patients and magnetic 
resonance angiography (MRA) or CT angiography (CTA) was performed where 
deemed appropriate by the treating physician to establish concordance between CDUS 
and another imaging modality. TIA and stroke work-up was performed according to 
European Stroke Organisation guidelines.[27] All late stage symptomatic carotid 
stenosis patients were phoned before their appointment to stress the importance of 
medication adherence in the week prior to assessment. Patients who were not adherent 
to their antithrombotic regimen were invited back for reassessment after 14 days. All 
patients were advised to immediately contact their attending physician and to inform 
the PACS research study staff if they had any recurrent vascular events whilst 
awaiting study follow up. Data on recurrent TIA, stroke, angina, MI, worsening 
symptomatic peripheral vascular disease, the need for coronary or peripheral arterial 
interventional treatment or vascular death were recorded prospectively in all 
symptomatic subjects at their last follow up visit. 
 
To establish the normal range of platelet function assays in the laboratory, a group of 
healthy controls of similar age and sex, with no history of known cerebrovascular 
disease, were recruited from the local population and from amongst the family 
members of the participating subjects. Controls had colour Doppler ultrasound of 
carotid and vertebral arteries (CDUS) to exclude asymptomatic ≥ 50% carotid 
stenosis prior to inclusion. Subjects were also excluded from the control group if they 
were on antiplatelets or NSAIDs, or had any other exclusion criteria that applied to 
patients. 
 
Blood sampling and laboratory tests: 
All subjects were rested for at least 20 minutes, and careful venepuncture was 
performed from a free-flowing vein using a sterile 21G Butterfly needle 
(VenisystemsTM, Abbott, Ireland) and a Vacutainer® system with a luer adaptor 
(Becton Dickinson Vacutainer Systems, UK). Venepuncture was performed using a 
standardised manner as described previously.[19] Platelet function/on-treatment 
reactivity was assessed with the PFA-100®, to measure C-ADP and C-EPI closure 
times in citrate-anticoagulated whole blood between 2 and 2.5 hours after 
venepuncture. The PFA-100 activates platelets by exposure to moderately high shear 
stress (5000 - 6000 s-1) and biochemical stimulation with collagen and either 
epinephrine (C-EPI cartridge) or ADP (C-ADP cartridge).[28,29] The time taken for 
activated platelets to occlude an aperture in the cartridge is called the closure time; the 
maximum closure time recorded by the device is 300 s, and we arbitrarily defined 
closure times above 300 s as 301 s for statistical analyses.  
 
Transcranial Doppler ultrasound: 
Bilateral simultaneous 1 hour-TCD recordings of the MCA were performed by one of 
two highly-experienced operators (JAK or WOT) with a Viassys Pioneer TC8080, as 
described previously.[19]  
 
Statistical Methods 
Descriptive statistical calculations were performed to calculate the percentage of 
patients on different antiplatelet regimens. Paired or unpaired t-tests were used for 
comparison of paired and unpaired parametric variables, respectively. The Wilcoxon 
signed rank test and the Wilcoxon rank sum test were used for comparison of paired 
and unpaired non-parametric variables, and the Kruskal-Wallis rank sum test for 
comparison of multiple non-parametric variables, where appropriate. Chi-squared or 
Fisher exact tests were used to compare changes in proportions between subject 
groups. 
 
We established laboratory normal ranges for the PFA-100 assays in 18 healthy 
controls (mean age 62 years; 72% male), as outlined above. For the purpose of this 
study, we considered patients to have ex-vivo HTPR on the PFA-100 if they had 
evidence of platelet ‘hyper-reactivity’ on the relevant PFA-100 cartridge despite 
treatment with their prescribed antiplatelet regimen. Therefore, (a) ex-vivo HTPR on 
aspirin was defined as failure to prolong the C-EPI closure time beyond the mean + 2 
standard deviations of our control range (162s) in patients on aspirin monotherapy, 
aspirin-dipyridamole or aspirin-clopidogrel combination therapy. (b) Ex-vivo HTPR 
on clopidogrel was defined as failure to prolong the CADP closure time beyond the 
mean + 2 standard deviations of our control range (165s) in patients on clopidogrel 
monotherapy, or clopidogrel in combination with aspirin as per usual ‘cross sectional, 
case-control’ definitions in the literature at the time of planning this study.[7,30] P 
<0·05 was considered to be statistically significant. All statistical calculations were 
performed using R, version 2.11.0.[31] 
 
The study was approved by the local Research Ethics Committee at St James’s 
Hospital / AMNCH (Project/REC Reference: 2007/03/01). Written informed consent, 
or assent from a relative, where appropriate, was obtained from all participants. 
 
Results 
31 asymptomatic and 46 patients with early (≤4 weeks) symptomatic carotid stenosis 
or occlusion had platelet function data available for analysis. Thirty-five of these 
symptomatic patients had follow up data at the late stage after symptom onset or 
carotid intervention (Table 1), 22 of whom had undergone CEA and 1 had 
endovascular treatment with stenting. As reported previously, two patients had 
recurrent ‘perioperative’ ischaemic stroke following carotid endarterectomy: one 
awoke following endarterectomy with a new ischaemic stroke, and one developed 
symptoms 48 hours postoperatively.[32] Moderate to severe carotid restenosis was 
noted in 3 patients on follow-up CDUS.[32] 
 
Assessment of Platelet Reactivity: 
There were no significant differences in median C-EPI or C-ADP closure times 
between the entire asymptomatic vs. early or late symptomatic groups, regardless of 
antiplatelet treatment regimens (Table 2). There were no differences in the prevalence 
of HTPR between the subgroups of asymptomatic vs. early or late phase symptomatic 
patients who were on aspirin or clopidogrel overall. However, the prevalence of 
aspirin-HTPR on the C-EPI cartridge was lower in the ‘late symptomatic post-
intervention subgroup’ than in the asymptomatic carotid stenosis subgroup on aspirin 
monotherapy (10% vs. 50%, p = 0.03; Table 2). There were no significant differences 
in vascular risk factors between these subgroups. 
 
Amongst all symptomatic patients with longitudinal data in both the early and late 
phases after symptom onset or intervention, median C-EPI closure times increased 
from the early to late phases (143s vs. 203s, p = 0.03; Table 3a). Amongst 
symptomatic patients on aspirin, alone or in combination with other antithrombotic 
therapy, median C-EPI closure times also increased (p = 0.023), and the proportion of 
patients with HTPR fell from the early to late phases after symptom onset or 
intervention (p = 0.01). Similar results were seen in symptomatic patients on aspirin 
monotherapy, with a reduction in the prevalence of aspirin-HTPR on the C-EPI 
cartridge during follow up from the early to late phases (p = 0.016; Table 3a). There 
was a significant reduction in aspirin-HTPR between the early and late post-
intervention phases in symptomatic patients with matched data who were on aspirin 
monotherapy (50% vs. 0%; p=0.02), but the number of subjects in this subgroup 
analysis was very limited (N = 8; Table 3b). 
Platelet Reactivity in MES-positive and MES-negative subgroups: 
Twenty-five asymptomatic, 31 early symptomatic and 27 late symptomatic patients 
had TCD data available for analysis.[19] As reported previously, 12% of 
asymptomatic vs. 32% of early symptomatic (p=0.02) and 19% late symptomatic 
patients (p=0.2) were MES +ve.[9,19,32] There were no significant differences in 
median C-EPI or C-ADP closure times between MES + ve vs. MES -ve subjects 
within the asymptomatic, early symptomatic, or late symptomatic subgroups (p≥0.16). 
There were no significant differences in HTPR status between asymptomatic vs. early 
or late symptomatic MES +ve patients, or between asymptomatic vs. early or late 
symptomatic MES -ve patients (p≥0.32). 
 
Relationship between HTPR status and clinical outcome events: 
Interestingly, one of the 2 symptomatic patients who developed perioperative 
recurrent stroke was taking aspirin-clopidogrel combination therapy and displayed 
HTPR on both the C-ADP and C-EPI cartridges in the early stage. The other 
symptomatic patient with perioperative stroke did not have HTPR on aspirin-
dipyridamole in the early stage. Therefore, one could not comment on any clear 
association between HTPR status and the incidence of recurrent vascular events due 
to the limited number of outcome events in this study. 
 
Discussion 
This novel, pilot study has revealed several interesting findings. The lack of 
differences in on-treatment platelet reactivity / platelet adhesion-aggregation on this 
moderately high shear stress device in asymptomatic vs. early symptomatic patients 
overall may partly reflect the fact that the stenosing atherosclerotic carotid plaque 
exposed circulating platelets to similar levels of shear stress in vivo in both patient 
groups initially [7,33-36], and the PFA-100 was not sensitive enough at detecting 
differences between groups. The lack of significant differences in C-EPI closure times 
between asymptomatic and early symptomatic patients also likely reflects that fact 
that similar antiplatelet regimens were used in each group initially (predominantly 
aspirin), and C-EPI closure times are highly sensitive to the effects of aspirin.[7,37] 
Although there were no statistically significant differences in on-treatment platelet 
reactivity between asymptomatic and late symptomatic patients overall, this likely 
reflects a type II error because there were non-significant trends towards more 
prolonged median C-EPI closure times and a lower prevalence of HTPR in late 
symptomatic compared with asymptomatic patients (table 2). We do not think that 
these late symptomatic C–EPI results were likely to have been significantly 
influenced by the more frequent use of aspirin and dipyridamole combination therapy 
in late symptomatic than asymptomatic patients, because previous data from our 
group have shown that the addition of dipyridamole to aspirin may prolong C-ADP, 
but not C-EPI closure times following TIA or ischaemic stroke.[38] Our preliminary 
subgroup data suggest that successful interventional treatment may even reduce the 
prevalence of aspirin-HTPR, as measured on the C-EPI cartridge, in symptomatic 
patients to lower levels than in asymptomatic patients on aspirin monotherapy. 
However, one must emphasise that this latter finding is subject to a type I error 
because the number of subjects included in this latter subgroup analysis was far too 
small to make any definitive conclusions; larger longitudinal studies are warranted to 
confirm or refute these potentially important subgroup findings. 
 
The longitudinal C-EPI data in the symptomatic group are also interesting, and 
indicate that the prevalence of antiplatelet-HTPR falls as one is followed from the 
early to the late phase after symptom onset or intervention, including those on aspirin 
monotherapy. These results most likely partly reflect the effects of successful 
removal/treatment of the stenosing carotid plaque in the majority of symptomatic 
patients, as well as resolution of the acute phase response over time in patients treated 
with modern secondary preventive treatment. Larger, longitudinal studies assessing 
the same patients before and after changing antiplatelet therapy [38] are needed to 
adequately assess the impact of changing antiplatelet therapy on HTPR status in 
patients with carotid stenosis. Such studies will allow one to determine whether 
patients who exhibit a reduction in on-treatment platelet reactivity in response to 
commencing or changing antiplatelet treatment will have a lower risk of recurrent 
vascular events than patients who do not exhibit such a dynamic change.  
 
Data from the C-ADP cartridge in patients on clopidogrel were not informative in this 
study. Our group and others have since shown that this cartridge is not sensitive to the 
anti-platelet effects if clopidogrel ex vivo when one uses a cross-sectional definition of 
clopidogrel-HTPR.[12,30,37] 
 
We chose to initially assess platelet function with the PFA-100 in this novel pilot 
study because platelets in patients with ≥50% carotid stenosis are believed to be 
exposed to at least moderate-high levels of shear stress in vivo.[33,35], and we wanted 
to mimic these shear stress conditions ex vivo. It is possible that one might derive 
more informative data on HTPR if one were to use an ex vivo test of platelet function 
that exposed platelets to low shear stress, variable levels of shear stress, or simply 
stirred the platelets in solution, to avoid excessive exposure of platelets to high shear 
stress both in vivo and ex vivo. These experiments are ongoing in our lab, and data are 
awaited. 
 
We did not find significant differences in on-treatment platelet reactivity in MES +vs 
subjects when compared with MES -ve subjects with asymptomatic or symptomatic 
carotid stenosis. This may reflect a type I error because the number of subjects 
included in this study was relatively small, but as stated above, this device may not be 
sensitive enough at detecting differences in HTPR status between asymptomatic and 
symptomatic patients overall before they undergo intervention.  
 
In conclusion, these pilot, proof-of-concept studies have shown that platelet 
function/reactivity monitoring with a moderately high shear stress testing platform 
may identify dynamic changes in HTPR status in symptomatic vs. asymptomatic 
moderate-severe carotid stenosis subgroups, and in symptomatic patients over time.  
Larger, longitudinal studies are warranted to reassess the impact of more intensive 
secondary preventive and interventional treatment on ex vivo platelet function at 
different levels of shear stress to determine whether monitoring HTPR status may 
facilitate optimised, individualised stroke prevention in patients with carotid stenosis.  
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Table 1: Demographic Data and Risk Factor Profile of Patients. P values relate to chi-squared or Fisher 
exact testing between asymptomatic and symptomatic carotid stenosis groups. Values are Means (±SD) 
or absolute counts 
Parameter 
Asymptomatic 
Carotid Stenosis 
(N = 31) 
Early Symptomatic 
Carotid Stenosis (N=46) 
Late Symptomatic 
Carotid Stenosis (N=35) 
Mean age (years) 68.2 (± 7.95) 65.0 (± 9.58) 65.0 (±9.9) 
p value  0.78 0.78 
Gender (M; %) 18 (58%) 28 (61%) 20 (57%) 
p value   0.8 0.94 
Median interval from symptom 
onset (days; range) 
N/A 7.5 (0 - 27) 175 (99 – 360) 
Degree of Stenosis:    
         (moderate:≥50 – 69%) 11 (35%) 7 (15%) 15 (43%) 
p value  0.039 0.54 
         (severe: ≥ 70 – 99%) 20 (65%) 33 (72%) 9 (26%) 
p value  0.50 0.0015 
         (occlusion) 0 6 (13%) 4 (11%) 
p value  0.04 0.07 
Antiplatelet therapy:    
         Aspirin monotherapy 22 (71%) 35 (76%) 15 (43%) 
p value  0.62 0.02 
        Aspirin /Dipyridamole                                                                                                                                                                                                                                                                                                           
combination 
2 (6%) 4 (9%) 11 (31%) 
p value  0.54 0.01 
        Clopidogrel monotherapy 5 (16%) 2 (4%) 6 (17%) 
p value  0.09 0.6 
        Aspirin /Clopidogrel 
combination 
2 (6%) 5 (11%) 3 (9%) 
p value  0.4 0.6 
Ischemic heart disease 7 (23%) 10 (22%) 7 (20%) 
p value  0.93 0.8 
Hypertension 27 (87%) 29 (63%) 23 (66%) 
p value  0.02 0.04 
Diabetes Mellitus 7 (23%) 8 (17%) 6 (17%) 
p value  0.57 0.58 
Prior TIA/Stroke before index 
event 
8 (26%) 7 (15%) 6 (17%) 
p value  0.25 0.39 
Family History Stroke 9 (29%) 16 (35%) 12 (34%) 
p value  0.6 0.65 
Prior venous thromboembolism 1 (3%) 0 0 
p value  0.4 0.5 
Peripheral Vascular Disease  5 (16%) 5 (11%) 6 (17%) 
p value  0.5 0.91 
Migraine (with or without aura) 6 (19%) 5 (11%) 5 (14%) 
p value  0.3 0.58 
Current smokers 5 (16%) 21 (46%) 14 (40%) 
p value  0.007 0.03 
Ex-smoker 22 (71%) 17 (37%) 13 (37%) 
p value  0.003 0.006 
Never smoker 4 (13%) 8 (17%) 8 (23%) 
p value  0.59 0.3 
Statin therapy 28 (90%) 33 (72%) 27 (77%) 
p value  0.043 0.13 
Table 2: Comparison of platelet reactivity in asymptomatic versus early symptomatic, late stage 
symptomatic and late stage symptomatic post-intervention carotid stenosis patients. Values are medians 
(25th - 75th percentile). Significant p values in bold. HTPR = high on treatment platelet reactivity. 
PFA-100 Results 
Asymptomatic 
(N=31) 
Early 
Symptomatic 
(N=46) 
Late 
Symptomatic 
(N=35) 
Late 
Symptomatic 
post-
intervention 
(N=23) 
Entire Cohort     
C-EPI closure time (sec) 145 (124 – 229) 146 (112 – 240) 203 (123 – 301) 189 (139 – 253) 
P value  0.83 0.22 0.36 
C-ADP closure time (sec) 95 (80 – 103) 90 (78 – 100) 93 (74 – 109) 97 (79 – 113) 
P value  0.56 0.94 0.62 
 
Asymptomatic 
(N=26) 
Early 
Symptomatic 
(N=40) 
Late 
Symptomatic 
(N=29) 
 
Late 
Symptomatic 
post-
intervention 
(N=19) 
Subgroup on Aspirin 
(Alone or in Combination 
with Dipyridamole or 
Clopidogrel) 
 
 
 
 
C-EPI closure time (sec) 164 (131 – 278) 152 (115 – 295) 223 (165 – 301) 204 (166 – 289) 
P value  0.55 0.27 0.56 
Number (%) with HTPR on 
C-EPI cartridge 
12 (46%) 22 (55%) 8 (28%) 4 (21%) 
P value  0.48 0.15 0.08 
 
Asymptomatic 
(N=22) 
Early 
Symptomatic 
(N=30) 
Late 
Symptomatic 
(N=15) 
 
Late 
Symptomatic 
post-
intervention 
(N=10) 
Aspirin Monotherapy 
Subgroup 
 
 
 
 
C-EPI closure time (sec) 148 (131 – 221) 169 (121 – 301) 205 (166 – 301) 203 (167 – 205) 
P value  0.66 0.17 0.27 
Number (%) with HTPR on 
C-EPI cartridge 
11 (50%) 15 (50%) 3 (20%) 1 (10%) 
P value  1.0 0.09 0.03 
 
Asymptomatic 
(N=7) 
Early 
Symptomatic 
(N=6) 
Late 
Symptomatic 
(N=9) 
 
Late 
Symptomatic 
post-
intervention 
(N=6) 
Clopidogrel Subgroup 
(Alone or in Combination 
with Aspirin) 
 
 
 
 
C-ADP closure time (sec) 97 (78 – 142) 93 (82 – 106) 120 (100 – 130) 128 (119 – 145) 
P value  1.0 0.46 0.25 
Number (%) with HTPR on 
C-ADP cartridge 
5 (71%) 5 (83%) 8 (89%) 5 (83%) 
P value  1.0 0.55 1.0 
 
Table 3a: Comparison of platelet reactivity between early and late phase 
symptomatic carotid stenosis patients with longitudinal data at both time points 
regardless of their prescribed antiplatelet regimen; those on aspirin alone or in 
combination with dipyridamole or clopidogrel; or aspirin monotherapy. Values 
are medians (25th - 75th percentile). Significant p values in bold. 
 
PFA-100 Results in Early Symptomatic (N=35) Late Symptomatic (N=35) P value 
Entire Symptomatic 
Subgroup with 
Longitudinal Data    
C-EPI closure time (sec) 143 (113 – 223) 203 (123 – 301) 0.03 
Number (%) with HTPR 
on C-EPI cartridge 22 (63%) 12 (34%) 0.017 
C-ADP closure time (sec) 89 (78 – 100) 93 (74 – 109) 0.48 
    
Symptomatic Subgroup 
on Aspirin (Alone or in 
Combination with 
Dipyridamole or 
Clopidogrel) Early Symptomatic (N=27) Late Symptomatic (N=27) P value 
C-EPI closure time (sec) 149 (115 – 263) 205 (150 – 301) 0.023 
Number (%) with HTPR 
on C-EPI cartridge 16 (59%) 7 (26%) 0.01 
C-ADP closure time (sec) 89 (78 – 96) 92 (73 – 99) 0.8 
    
Symptomatic Subgroup 
on Aspirin Monotherapy Early Symptomatic (N=13) Late Symptomatic (N=13) P value 
C-EPI closure time (sec) 152 (118 – 301) 205 (167 – 301) 0.15 
Number (%) with HTPR 
on C-EPI cartridge 8 (62%) 2 (15%) 0.016 
 
 
Table 3b: Comparison of ‘matched’ platelet reactivity data between early and 
late phase symptomatic carotid stenosis patients who underwent carotid 
intervention. Values are medians (25th - 75th percentile). Significant p values in 
bold. 
 
PFA-100 Results in 
Early Symptomatic 
(N=23) 
Late Symptomatic  
Post-intervention (N=23) P value 
Symptomatic Subgroup 
with Longitudinal Data 
pre- and post-intervention    
C-EPI closure time (sec) 146 (125 – 254) 191 (143 – 277) 0.32 
C-ADP closure time (sec) 92 (80 – 104) 97 (79 – 113) 0.53 
    
Symptomatic Subgroup on 
Aspirin Monotherapy 
Early Symptomatic 
(N=8) 
Late Symptomatic  
Post-intervention (N=8) P value 
PFA-100    
C-EPI closure time (sec) 231 (147 – 301) 204 (181 – 264) 1 
Number (%) with HTPR on 
C-EPI cartridge 4 (50%) 0 (0%) 0.02 
C-ADP closure time (sec) 89 (77 – 133) 99 (69 – 138) 0.69 
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